Kaplan-Meier curves depicting local recurrence-free probability in patients stratified by tamoxifen use.

Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance

Campbell, Christine
Mathew, John
Ellis, Ian O.
Bradbury, Ian
Borgquist, Signe
Elebro, Karin
Green, Andrew R.
Finlay, Pauline
Gee, Julia M. W.
Robertson, John F. R.

January 2020

Background: It remains clinically important to identify ER positive breast cancers likely to respond...

Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer

Kok, M. de
Koornstra, R.H.
Mook, S.
Hauptmann, M.
Fles, R.
Jansen, M.P.
Berns, E.M.
Linn, S.C.
Veer, L.J. van 't

January 2012

BACKGROUND: Breast cancer patients with node positive disease can have an excellent outcome with tam...

A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen

Ma, Xiao-Jun
Wang, Zuncai
Ryan, Paula D
Isakoff, Steven J
Barmettler, Anne
Fuller, Andrew
Muir, Beth
Mohapatra, Gayatry
Salunga, Ranelle
Tuggle, J.Todd
Tran, Yen
Tran, Diem
Tassin, Ana
Amon, Paul
Wang, Wilson
Wang, Wei
Enright, Edward
Stecker, Kimberly
Estepa-Sabal, Eden
Smith, Barbara
Younger, Jerry
Balis, Ulysses
Michaelson, James
Bhan, Atul
Habin, Karleen
Baer, Thomas M
Brugge, Joan
Haber, Daniel A
Erlander, Mark G
Sgroi, Dennis C

June 2004

AbstractTamoxifen significantly reduces tumor recurrence in certain patients with early-stage estrog...

ESR1 predicts response to tamoxifen on YTMA 130 Subset.

Jennifer M. Bordeaux (323306)
Huan Cheng (129416)
Allison W. Welsh (323309)
Bruce G. Haffty (228107)
Donald R. Lannin (323310)
Xingyong Wu (323311)
Nan Su (323312)
Xiao-Jun Ma (323313)
Yuling Luo (323314)
David L. Rimm (323315)

February 2013

Kaplan-Meier curves all show 10-year recurrence-free survival. (A) Cases from the YTMA 130 Subset...

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial

Dowsett, Mitch
Allred, Craig
Bishop, Hugh
Ellis, Ian
Larsimont, Danis
Sasano, Hironobu
Carder, Pauline
Cussac, Antonio L.
Knox, Fiona
Speirs, Valerie
Forbes, John
Buzdar, Aman
Knox, Jill
Quinn, Emma
Salter, Janine
Wale, Chris
Cuzick, Jack
Houghton, Joan
Williams, Norman
Mallon, Elizabeth

January 2008

Purpose: To determine the relationship between quantitative estrogen-receptor (ER) and progesterone-...

Tamoxifen induces ER-α36, HER2 and EGFR expression.

Li Yin (286335)
Xin-Tian Zhang (367433)
Xiu-Wu Bian (4358719)
Yu-Ming Guo (627698)
Zhao-Yi Wang (310751)

September 2014

Western blot analysis of the expression levels of ER-α66, ER-α36, HER2 and EGFR in ER-positive br...

Kaplan-Meier curves in terms of (A) time to progression (TTP) and (B) survival, according to HER3 mRNA expression, in HER2-positive patients treated with first-line trastuzumab.

Angelos Koutras (161081)
Georgios Lazaridis (537767)
Georgia-Angeliki Koliou (6057572)
George Kouvatseas (436149)
Christos Christodoulou (387781)
Dimitrios Pectasides (62261)
Vassiliki Kotoula (161014)
Anna Batistatou (64889)
Mattheos Bobos (53836)
Eleftheria Tsolaki (439179)
Kyriaki Papadopoulou (439181)
George Pentheroudakis (387784)
Pavlos Papakostas (53841)
Stavroula Pervana (6057575)
Kalliopi Petraki (684782)
Sofia Chrisafi (161038)
Evangelia Razis (53828)
Amanda Psyrri (62257)
Dimitrios Bafaloukos (161057)
Konstantine T. Kalogeras (161068)
Haralambos P. Kalofonos (586696)
George Fountzilas (8221)

February 2019

Kaplan-Meier curves in terms of (A) time to progression (TTP) and (B) survival, according to HER3 mR...

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen

Kok, M
Linn, SC
Van Laar, RK
Jansen, Maurice
Berg, Tineke
Delahaye, LJMJ
Glas, AM
Peterse, JL
Hauptmann, M (Michael)
Foekens, John
Klijn, Jan
Wessels, LFA
van 't Veer, LJ (Laura)
Berns, Els

January 2009

Background Molecular signatures that predict outcome in tamoxifen treated breast cancer patients hav...

Kaplan-Meier plots of recurrence free survival in breast cancer patients from the validation set predicted by the Tc/ClassII immune signature score in conjunction with the PCNA+ TAMs surrogate score.

Michael J. Campbell (5833)
Denise Wolf (477504)
Rita A. Mukhtar (477505)
Vickram Tandon (477506)
Christina Yau (62337)
Alfred Au (477507)
Frederick Baehner (294346)
Laura van’t Veer (477508)
Donald Berry (68656)
Laura J. Esserman (477509)

October 2013

(A) Kaplan-Meier curves for RFS comparing patients with a high PCNA+ TAMs surrogate sc...

RSF1 amplification and relapse-free survival.

Dana Keilty (499767)
Marguerite Buchanan (499768)
Katerina Ntapolias (499769)
Olga Aleynikova (499770)
Dongsheng Tu (392902)
Xiao Li (107004)
Lois Shepherd (499771)
Vivien Bramwell (499772)
Mark Basik (159698)

December 2013

RFS for patients with RSF1 gene amplification or not, showing benefit from tamoxifen in both grou...

St. Gallen endocrine response classes predict recurrence rates over time

Koornstra, R.H.
Beelen, K.J.
Vincent, A.D.
Noort, V van
Diest, P.J. van
Linn, S.C.

January 2015

Item does not contain fulltextBACKGROUND: In 2007 the St. Gallen consensus panel defined three endoc...

Survival curves for patients treated with Tamoxifen, related to Fig 7.

Oscar D. Murillo (11679112)
Varduhi Petrosyan (7434389)
Emily L. LaPlante (16828226)
Lacey E. Dobrolecki (147354)
Michael T. Lewis (12975307)
Aleksandar Milosavljevic (67345)

August 2023

(A) Survival curve showing no significant survival difference between patients classified as Luminal...

17β-Hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer.

Tove Sivik
Cecilia Gunnarsson
Tommy Fornander
Bo Nordenskjöld
Lambert Skoog
Olle Stål
Agneta Jansson

INTRODUCTION: 17β-Hydroxysteroid dehydrogenases (17βHSDs) are important enzymes regulating the pool ...

21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy

백순명

January 2017

Background: The 21-gene recurrence score (RS) predicts risk of locoregional recurrence (LRR) in node...

Kaplan-Meier curves: Distant metastasis-free (A) and overall (B) survival by tumor subtype.

Min-Young Lee (292407)
Won Jin Chang (3129210)
Hae Su Kim (2266702)
Ji Yun Lee (2266711)
Sung Hee Lim (2256862)
Jeong Eon Lee (13290)
Seok Won Kim (6449)
Seok Jin Nam (779396)
Jin Seok Ahn (416100)
Young-Hyuck Im (2266708)
Yeon Hee Park (2266705)

September 2016

ILRR, isolated locoregional recurrence; HR, hormone receptor; HER2, human epidermal growth factor...

Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance

Campbell, Christine
Mathew, John
Ellis, Ian O.
Bradbury, Ian
Borgquist, Signe
Elebro, Karin
Green, Andrew R.
Finlay, Pauline
Gee, Julia M. W.
Robertson, John F. R.

January 2020

Background: It remains clinically important to identify ER positive breast cancers likely to respond...

Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer

Kok, M. de
Koornstra, R.H.
Mook, S.
Hauptmann, M.
Fles, R.
Jansen, M.P.
Berns, E.M.
Linn, S.C.
Veer, L.J. van 't

January 2012

BACKGROUND: Breast cancer patients with node positive disease can have an excellent outcome with tam...

A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen

Ma, Xiao-Jun
Wang, Zuncai
Ryan, Paula D
Isakoff, Steven J
Barmettler, Anne
Fuller, Andrew
Muir, Beth
Mohapatra, Gayatry
Salunga, Ranelle
Tuggle, J.Todd
Tran, Yen
Tran, Diem
Tassin, Ana
Amon, Paul
Wang, Wilson
Wang, Wei
Enright, Edward
Stecker, Kimberly
Estepa-Sabal, Eden
Smith, Barbara
Younger, Jerry
Balis, Ulysses
Michaelson, James
Bhan, Atul
Habin, Karleen
Baer, Thomas M
Brugge, Joan
Haber, Daniel A
Erlander, Mark G
Sgroi, Dennis C

June 2004

AbstractTamoxifen significantly reduces tumor recurrence in certain patients with early-stage estrog...

ESR1 predicts response to tamoxifen on YTMA 130 Subset.

Jennifer M. Bordeaux (323306)
Huan Cheng (129416)
Allison W. Welsh (323309)
Bruce G. Haffty (228107)
Donald R. Lannin (323310)
Xingyong Wu (323311)
Nan Su (323312)
Xiao-Jun Ma (323313)
Yuling Luo (323314)
David L. Rimm (323315)

February 2013

Kaplan-Meier curves all show 10-year recurrence-free survival. (A) Cases from the YTMA 130 Subset...

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial

Dowsett, Mitch
Allred, Craig
Bishop, Hugh
Ellis, Ian
Larsimont, Danis
Sasano, Hironobu
Carder, Pauline
Cussac, Antonio L.
Knox, Fiona
Speirs, Valerie
Forbes, John
Buzdar, Aman
Knox, Jill
Quinn, Emma
Salter, Janine
Wale, Chris
Cuzick, Jack
Houghton, Joan
Williams, Norman
Mallon, Elizabeth

January 2008

Purpose: To determine the relationship between quantitative estrogen-receptor (ER) and progesterone-...

Tamoxifen induces ER-α36, HER2 and EGFR expression.

Li Yin (286335)
Xin-Tian Zhang (367433)
Xiu-Wu Bian (4358719)
Yu-Ming Guo (627698)
Zhao-Yi Wang (310751)

September 2014

Western blot analysis of the expression levels of ER-α66, ER-α36, HER2 and EGFR in ER-positive br...

Kaplan-Meier curves in terms of (A) time to progression (TTP) and (B) survival, according to HER3 mRNA expression, in HER2-positive patients treated with first-line trastuzumab.

Angelos Koutras (161081)
Georgios Lazaridis (537767)
Georgia-Angeliki Koliou (6057572)
George Kouvatseas (436149)
Christos Christodoulou (387781)
Dimitrios Pectasides (62261)
Vassiliki Kotoula (161014)
Anna Batistatou (64889)
Mattheos Bobos (53836)
Eleftheria Tsolaki (439179)
Kyriaki Papadopoulou (439181)
George Pentheroudakis (387784)
Pavlos Papakostas (53841)
Stavroula Pervana (6057575)
Kalliopi Petraki (684782)
Sofia Chrisafi (161038)
Evangelia Razis (53828)
Amanda Psyrri (62257)
Dimitrios Bafaloukos (161057)
Konstantine T. Kalogeras (161068)
Haralambos P. Kalofonos (586696)
George Fountzilas (8221)

February 2019

Kaplan-Meier curves in terms of (A) time to progression (TTP) and (B) survival, according to HER3 mR...

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen

Kok, M
Linn, SC
Van Laar, RK
Jansen, Maurice
Berg, Tineke
Delahaye, LJMJ
Glas, AM
Peterse, JL
Hauptmann, M (Michael)
Foekens, John
Klijn, Jan
Wessels, LFA
van 't Veer, LJ (Laura)
Berns, Els

January 2009

Background Molecular signatures that predict outcome in tamoxifen treated breast cancer patients hav...

Kaplan-Meier plots of recurrence free survival in breast cancer patients from the validation set predicted by the Tc/ClassII immune signature score in conjunction with the PCNA+ TAMs surrogate score.

Michael J. Campbell (5833)
Denise Wolf (477504)
Rita A. Mukhtar (477505)
Vickram Tandon (477506)
Christina Yau (62337)
Alfred Au (477507)
Frederick Baehner (294346)
Laura van’t Veer (477508)
Donald Berry (68656)
Laura J. Esserman (477509)

October 2013

(A) Kaplan-Meier curves for RFS comparing patients with a high PCNA+ TAMs surrogate sc...

RSF1 amplification and relapse-free survival.

Dana Keilty (499767)
Marguerite Buchanan (499768)
Katerina Ntapolias (499769)
Olga Aleynikova (499770)
Dongsheng Tu (392902)
Xiao Li (107004)
Lois Shepherd (499771)
Vivien Bramwell (499772)
Mark Basik (159698)

December 2013

RFS for patients with RSF1 gene amplification or not, showing benefit from tamoxifen in both grou...

St. Gallen endocrine response classes predict recurrence rates over time

Koornstra, R.H.
Beelen, K.J.
Vincent, A.D.
Noort, V van
Diest, P.J. van
Linn, S.C.

January 2015

Item does not contain fulltextBACKGROUND: In 2007 the St. Gallen consensus panel defined three endoc...

Survival curves for patients treated with Tamoxifen, related to Fig 7.

Oscar D. Murillo (11679112)
Varduhi Petrosyan (7434389)
Emily L. LaPlante (16828226)
Lacey E. Dobrolecki (147354)
Michael T. Lewis (12975307)
Aleksandar Milosavljevic (67345)

August 2023

(A) Survival curve showing no significant survival difference between patients classified as Luminal...

17β-Hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer.

Tove Sivik
Cecilia Gunnarsson
Tommy Fornander
Bo Nordenskjöld
Lambert Skoog
Olle Stål
Agneta Jansson

INTRODUCTION: 17β-Hydroxysteroid dehydrogenases (17βHSDs) are important enzymes regulating the pool ...

21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy

백순명

January 2017

Background: The 21-gene recurrence score (RS) predicts risk of locoregional recurrence (LRR) in node...

Kaplan-Meier curves: Distant metastasis-free (A) and overall (B) survival by tumor subtype.

Min-Young Lee (292407)
Won Jin Chang (3129210)
Hae Su Kim (2266702)
Ji Yun Lee (2266711)
Sung Hee Lim (2256862)
Jeong Eon Lee (13290)
Seok Won Kim (6449)
Seok Jin Nam (779396)
Jin Seok Ahn (416100)
Young-Hyuck Im (2266708)
Yeon Hee Park (2266705)

September 2016

ILRR, isolated locoregional recurrence; HR, hormone receptor; HER2, human epidermal growth factor...

Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance

Campbell, Christine
Mathew, John
Ellis, Ian O.
Bradbury, Ian
Borgquist, Signe
Elebro, Karin
Green, Andrew R.
Finlay, Pauline
Gee, Julia M. W.
Robertson, John F. R.

January 2020

Background: It remains clinically important to identify ER positive breast cancers likely to respond...

Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer

Kok, M. de
Koornstra, R.H.
Mook, S.
Hauptmann, M.
Fles, R.
Jansen, M.P.
Berns, E.M.
Linn, S.C.
Veer, L.J. van 't

January 2012

BACKGROUND: Breast cancer patients with node positive disease can have an excellent outcome with tam...

A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen

Ma, Xiao-Jun
Wang, Zuncai
Ryan, Paula D
Isakoff, Steven J
Barmettler, Anne
Fuller, Andrew
Muir, Beth
Mohapatra, Gayatry
Salunga, Ranelle
Tuggle, J.Todd
Tran, Yen
Tran, Diem
Tassin, Ana
Amon, Paul
Wang, Wilson
Wang, Wei
Enright, Edward
Stecker, Kimberly
Estepa-Sabal, Eden
Smith, Barbara
Younger, Jerry
Balis, Ulysses
Michaelson, James
Bhan, Atul
Habin, Karleen
Baer, Thomas M
Brugge, Joan
Haber, Daniel A
Erlander, Mark G
Sgroi, Dennis C

June 2004

AbstractTamoxifen significantly reduces tumor recurrence in certain patients with early-stage estrog...

Kaplan-Meier curves depicting local recurrence-free probability in patients stratified by tamoxifen use.

Abstract

Extracted data

Kaplan-Meier curves depicting local recurrence-free probability in patients stratified by tamoxifen use.

Abstract

Extracted data

Related items

Related items